This study explored the therapeutic effect and molecular mechanisms of anlotinib in a model of papillary thyroid carcinoma (PTC) with BRAFV600E and TERT promoter cooccurring mutations, providing a theoretical basis for identifying biomarkers for predicting the effectiveness of anlotinib treatment in radioactive iodine refractory (RAIR)-PTC.